TransMedics Group, Inc. Common Stock TMDX

TransMedics Group, Inc. es una empresa de tecnología médica en etapa comercial. La empresa se enfoca en desarrollar terapias de trasplante de órganos para pacientes con falla orgánica terminal en múltiples estados de enfermedad. La empresa ha diseñado y desarrollado un sistema de cuidado de órganos (OCS), un sistema portátil de perfusión, optimización y monitoreo de órganos que utiliza su tecnología personalizada para replicar condiciones casi fisiológicas para los órganos donantes fuera del cuerpo humano. Diseñó su plataforma tecnológica OCS para perfundir los órganos donantes con sangre tibia, oxigenada y enriquecida con nutrientes, manteniendo los órganos en un estado vivo y funcional. Ha desarrollado tres productos OCS, uno para trasplante de pulmón, corazón e hígado respectivamente. Sus productos incluyen OCS Heart, OCS Lung y OCS Liver. Su producto OCS consta de tres componentes personalizados para cada órgano, que incluyen la Consola OCS, el Set de Perfusión OCS y las Soluciones OCS. También está desarrollando productos OCS para órganos adicionales, incluidos los riñones.

• Zacks Investment Research 3 sept

  Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

  TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.

  

• GlobeNewswire Inc. 2 sept

  TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

  Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offers legal representation for affected investors.

  

• GlobeNewswire Inc. 29 ago

  TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

  Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offering legal representation for affected investors.

  

• GlobeNewswire Inc. 9 ago

  ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MVST

  Rosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.

  

• GlobeNewswire Inc. 8 ago

  TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

  Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. The firm is seeking shareholders who currently own TMDX stock to join the investigation.